Individualized antithrombotic therapy in high-risk cardiovascular patients

被引：1

作者：

Tegtmeyer, Roland ^{[1
]}

Borst, Oliver ^{[1
]}

Gawaz, Meinrad ^{[1
]}

Rath, Dominik ^{[1
]}

机构：

[1] Univ Tubingen, Dept Cardiol & Cardiovasc Med, Tubingen, Germany

来源：

PERSONALIZED MEDICINE | 2018年 / 15卷 / 03期

关键词：

bleeding; coronary artery disease; drug-eluting stent; dual antiplatelet therapy; high risk; myocardial infarction; DUAL-ANTIPLATELET THERAPY; ELUTING STENT IMPLANTATION; RESIDUAL PLATELET-AGGREGATION; CORONARY-ARTERY-DISEASE; ESC FOCUSED UPDATE; MYOCARDIAL-INFARCTION; CLOPIDOGREL; DURATION; THROMBOSIS; MORTALITY;

D O I：

10.2217/pme-2017-0081

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Recent guidelines suggest dual antiplatelet therapy (DAPT) after 'drug-eluting' stent (DES) implantation for 6 months in stable patients and for 12 months in patients after acute coronary syndrome. Serious complications after stent implantation include stent thrombosis, recurrent myocardial infarction, ischemic stroke, cardiovascular death and bleeding. These complications also occur beyond 1 year after coronary intervention. Thus, it is important to consider whether a prolonged DAPT (>12 months after percutaneous coronary intervention) is of benefit to lower thrombo-ischemic events in high-risk patients. This review addresses the results of recent randomized clinical studies (DAPT, ITALIC, OPTIDUAL and PEGASUS) and meta-analyses to support the author's view of which patient collectives might benefit from prolonged DAPT.

引用

页码：223 / 236

页数：14

共 50 条

[1] Antithrombotic therapy in high-risk pregnancy
Heilmann, L
Schneider, DM
von Tempelhoff, GF
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2000, 14 (05) : 1133 - +
[2] Strategies of antithrombotic therapy in patients with low-risk and high-risk PTCA
Silber, S
Dorr, R
HERZ, 1996, 21 (01) : 44 - 59
[3] Individualized antithrombotic therapy
Luescher, T. F.
Steffel, J.
HAMOSTASEOLOGIE, 2016, 36 (01): : 26 - 32
[4] COVID-19: Individualized Therapy for venous Thromboembolism (VTE) in High-risk Patients
不详
TRANSFUSION MEDICINE AND HEMOTHERAPY, 2020, 47 (06) : 473 - 473
[5] Working with High-risk Adolescents: An Individualized Family Therapy Approach
Hilarski, Carolyn
JOURNAL OF EVIDENCE-INFORMED SOCIAL WORK, 2018, 15 (03): : 332 - 334
[6] Working With High-Risk Adolescents: An Individualized Family Therapy Approach
Paul, Howard A.
CHILD & FAMILY BEHAVIOR THERAPY, 2018, 40 (01) : 99 - 106
[7] The cardiovascular polypill in high-risk patients
Lafeber, Melvin
Spiering, Wilko
Singh, Kavita
Guggilla, Rama K.
Patil, Vinodvenkatesh
Webster, Ruth
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2012, 19 (06) : 1234 - 1242
[8] INCIDENCE OF GASTROINTESTINAL BLEEDING IN HIGH-RISK CARDIOVASCULAR PATIENTS TAKING ANTITHROMBOTIC MEDICATIONS WITH PROTON PUMP INHIBITORS
Edwards, Mark
Kong, Xiaowen
Kurlander, Jacob
Kaatz, Scott
Froehlich, James B.
Tassava, Twylla
Giuliano, Christopher
Barnes, Geoffrey D.
AMERICAN JOURNAL OF HEMATOLOGY, 2024, 100 : 42 - 43
[9] Rotational Thromboelastometry in High-Risk Patients on Dual Antithrombotic Therapy After Percutaneous Coronary Intervention
Hulshof, Anne-Marije
Olie, Renske H.
Vries, Minka J. A.
Verhezen, Paul W. M.
van der Meijden, Paola E. J.
ten Cate, Hugo
Henskens, Yvonne M. C.
FRONTIERS IN CARDIOVASCULAR MEDICINE, 2021, 8
[10] PREVALENCE OF THERAPY-RESISTANT HYPERCHOLESTEROLEMIA IN HIGH-RISK CARDIOVASCULAR PATIENTS IN GERMANY
Kostev, K.
Parhofer, K.
Dombrowski, S.
Dippel, F.
VALUE IN HEALTH, 2016, 19 (07) : A659 - A659

← 1 2 3 4 5 →